Hit ‘enter’ to search full site for “Search query”
Read our recent announcements about our company, our research, and partnerships.
Dr Raphael Bernier joins the Board as a Non-Executive Director
Formation of new partnership with the SHANK2 Foundation, a U.S.-based not-for-profit organisation with a focus on advocacy, awareness, the creation of research infrastructure.
BlinkLab announced that Drexel University has joined as a clinical site for the Company’s pivotal U.S. regulatory trial for BlinkLab Dx 1.
BlinkLab receives R&D Tax Incentive Refund relating to its U.S. Pilot Study and Australian clinical research initatives
BlinkLab Dx 1 achieved 83.7% sensitivity and 84.7% specificity in a clinically diverse pediatric population, confirming robust real-world diagnostic performance.
BlinkLab is thrilled to share the successful outcome of its Pre-Submission meeting with the FDA, marking a critical step toward achieving 510(k) clearance for its innovative autism diagnostic app, BlinkLab Dx 1. With the study design and data requirements now confirmed, BlinkLab is poised to initiate a robust clinical program that will pave the way for regulatory approval and market entry in the US.
BlinkLab showcases smartphone-mediated neurobehavioral testing as a digital biomarker at Neuroscience 2022.
Sam Wang highlights the science and vision behind BlinkLab’s neurobehavioral tools at Princeton’s innovation showcase.
A major step we are proud to share!
BlinkLab closes seed round!
